Plague (Pneumonic)

Pneumonic plague is the most severe and rapidly fatal form of plague caused by Yersinia pestis, with mortality rates approaching 100% if untreated and over 50% even with appropriate antimicrobial therapy. [1] This highly contagious form requires immediate recognition and aggressive treatment.

Key HPI questions

• Onset and progression of fever, cough, and dyspnea (typically 1-6 days, most often 2-4 days after exposure) [2]

• Hemoptysis - bloody, watery, or purulent sputum production [2]

• Chest pain (pleuritic) and dyspnea severity [3]

• Gastrointestinal symptoms: nausea, vomiting, abdominal pain, diarrhea [2]

• Recent travel to endemic areas (western US, Madagascar, Democratic Republic of Congo) [4]

• Animal exposure history (rodents, cats, marmots, prairie dogs) [5]

• Contact with sick individuals or attendance at funerals [6]

Timing and progression

• Incubation period: few hours to 2-3 days [3]

• Rapid progression to respiratory failure within 2-6 days [2]

• Sudden onset with high fever [3]

Important negatives

• Absence of buboes (except rarely cervical) distinguishes primary from secondary pneumonic plague [2]

Red flag symptoms/signs

• Hemoptysis - unique feature distinguishing from ordinary pneumonia [7]

• Rapid progression to respiratory failure within 24-48 hours [5][7]

• High fever with severe dyspnea and cough [3]

• Altered mental status, coma [5]

• Prominent gastrointestinal symptoms with respiratory illness [2]

Life-threatening indicators

• Signs of sepsis and multiorgan failure [2]

• Coagulation abnormalities and bleeding [2]

• Bilateral pulmonary infiltrates [2]

• Death can occur within 48 hours of symptom onset [5]

Contraindicated medications

• Penicillin - associated with 75% case fatality rate [8]

• Beta-lactam antibiotics less effective than aminoglycosides or quinolones [3]

Treatment considerations

• Delay in antibiotic treatment beyond 24 hours significantly increases mortality [2]

• Dual therapy recommended for severe cases and bioterrorism scenarios [9]

Acute management

• NPO if severe illness or intubated

• Maintain hydration and electrolyte balance

• Nutritional support as tolerated during recovery

High-yield ROS questions

• Constitutional: fever, chills, malaise, headache [9]

• Respiratory: cough, hemoptysis, chest pain, dyspnea [3]

• Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea [2]

• Neurologic: altered mental status, agitation, prostration [3]

• Skin: petechial bleeding, purpura (late findings) [2]

Important collateral information

• Recent deaths in household or community [6]

• Attendance at funerals or care of sick individuals [6]

• Travel companions with similar illness

• Occupational exposure (veterinarians, hunters) [1]

Family history

• No specific hereditary predisposition

• Household contacts at high risk for transmission [9]

Major risk factors

• Geographic exposure: endemic areas (western US, Madagascar, DRC) [4]

• Animal contact: rodents, cats, marmots, prairie dogs [5]

• Occupational: hunters, veterinarians, laboratory workers [1]

• Poverty: increased rodent exposure [1]

• Close contact with pneumonic plague patients (<6 feet) [9]

Special populations

• Children equally susceptible but not at higher risk for complications [9]

• Pregnant women: risk of hemorrhage, fetal demise, preterm birth [9]

Most important alternative diagnoses

• Community-acquired pneumonia (S. pneumoniae, H. influenzae, S. aureus)

• Atypical pneumonia (Mycoplasma, Legionella, Chlamydia)

• Viral pneumonia with bacterial superinfection

• Hantavirus pulmonary syndrome (if rodent exposure)

• Tularemia (if animal exposure)

Dangerous cannot-miss diagnoses

• Bioterrorism-related pneumonic plague [9]

• Severe acute respiratory syndrome (SARS)

• Anthrax pneumonia

• Melioidosis

Distinguishing features

• Hemoptysis more prominent in plague [7]

• Rapid progression and high mortality [1]

• Gastrointestinal symptoms common in plague [2]

• Geographic and exposure history crucial [4]

Relevant conditions

• Previous plague episodes (rare)

• Immunocompromising conditions

• Chronic respiratory disease

• Recent antibiotic use affecting culture results [1]

Key exam findings

• Vital signs: high fever, tachypnea, tachycardia, hypotension [2]

• Pulmonary: bilateral rales, consolidation, decreased breath sounds [2]

• Lymph nodes: cervical lymphadenopathy (rare in primary pneumonic) [2]

• Skin: petechiae, purpura (late findings) [2]

• Neurologic: altered mental status, agitation [3]

Expected vs concerning findings

• Absence of buboes expected in primary pneumonic plague [2]

• Signs of sepsis and shock indicate severe disease [2]

Recommended labs

• Complete blood count: leukocytosis with toxic granulations [2]

• Comprehensive metabolic panel: aminotransferase elevations, azotemia [2]

• Coagulation studies: PT/PTT, fibrinogen, D-dimer [2]

• Blood cultures (usually positive) [3]

• Sputum culture and Gram stain [2]

Expected abnormalities

• Leukocytosis with left shift [2]

• Elevated liver enzymes [2]

• Coagulation abnormalities [2]

• Evidence of multiorgan failure [2]

Specialized testing

• F1 antigen rapid dipstick test (if available in endemic areas) [6]

• PCR for pla gene (reference laboratory) [3]

• Wright-Giemsa or Wayson stain showing bipolar staining [2]

First-line imaging

• Chest X-ray: bilateral infiltrates or consolidation common [2]

• Variable patterns: lobar consolidation, nodular infiltrates, pleural effusion [9]

CT findings

• Multiple nodules in central lung regions [5]

• Consolidation in secondary pulmonary lobules [5]

• Gravity-dependent distribution pattern [5]

• Findings consistent with pulmonary hemorrhage and diffuse alveolar damage [5]

When imaging unnecessary

• Should not delay antibiotic treatment [2]

Diagnostic tests

• F1 antigen dipstick test (rapid, field-deployable) [6]

• Direct fluorescent antibody testing [2]

• Bacteriophage lysis test for confirmation [3]

Point-of-care tests

• F1 rapid diagnostic test (70% specificity for pneumonic plague) [1]

ECG considerations

• Not routinely indicated unless cardiac complications suspected

• May show tachycardia, signs of strain from sepsis

• Monitor for arrhythmias in severe sepsis

Clinical summary

• Pneumonic plague is a medical emergency requiring immediate antibiotic therapy [1]

• Case fatality rate: 25-50% even with treatment [1][4]

• Rapid progression from symptom onset to death (2-6 days historically) [2]

Severity stratification

• Severe: respiratory failure, sepsis, multiorgan dysfunction [2]

• Moderate: stable vital signs but pneumonic symptoms

• Complications: ARDS, DIC, shock, multiorgan failure [2]

Initial stabilization

• Immediate isolation with droplet precautions [7]

• Aggressive supportive care for sepsis and respiratory failure [3]

• Empirical antibiotics - do not delay for confirmatory testing [2]

First-line antibiotics (10-14 days): [9]

• Ciprofloxacin: 400 mg IV q8h or 750 mg PO q12h

• Levofloxacin: 750 mg IV/PO daily

• Gentamicin: 5 mg/kg IV daily

• Streptomycin: 1 g IM/IV q12h

Alternative antibiotics: [9]

• Doxycycline: 200 mg loading dose, then 100 mg q12h

• Chloramphenicol: 12.5-25 mg/kg IV q6h (max 1 g/dose)

Dual therapy recommended for: [9]

• Severe pneumonic or septicemic plague

• Suspected bioterrorism cases

• Use two distinct antibiotic classes until sensitivities known

Admission criteria

• All suspected pneumonic plague cases require hospitalization [4]

• ICU admission for respiratory failure, sepsis, or multiorgan dysfunction

• Isolation with droplet precautions for minimum 48 hours of effective treatment [9]

Discharge criteria

• Clinical improvement with decreased sputum production [9]

• Completed 48 hours of effective antimicrobial therapy [9]

• Stable vital signs and adequate oral intake

Specialist consultation

• Infectious disease consultation recommended

• Pulmonology if respiratory failure

• Public health notification mandatory [10]

Follow-up timing

• Daily monitoring during first 3 days of treatment [4]

• Weekly follow-up until treatment completion

• Contact tracing and prophylaxis coordination [10]

Return precautions

• Worsening respiratory symptoms despite treatment

• New fever or clinical deterioration

• Signs of treatment failure or complications

Patient counseling

• Droplet precautions until 48 hours of effective treatment [9]

• Contact identification for prophylaxis [9]

• Medication compliance critical for survival

• Expected recovery course: gradual improvement over 7-14 days with appropriate treatment

Public health measures

• Immediate reporting to local health department [10]

• Contact tracing and postexposure prophylaxis [9]

• Infection control measures in healthcare settings [9]

1. Rapid Diagnostic Tests for Plague. — Jullien S, Dissanayake HA, Chaplin M. The Cochrane Database of Systematic Reviews. 2020.

2. Plague as a Biological Weapon: Medical and Public Health Management. — Inglesby TV, Dennis DT, Henderson DA, et al. The Journal of the American Medical Association. 2000.

3. Plague. — Prentice MB, Rahalison L. Lancet. 2007.

4. Ciprofloxacin versus Aminoglycoside–Ciprofloxacin for Bubonic Plague. — Randremanana RV, Raberahona M, Bourner J, et al. The New England Journal of Medicine. 2025.

5. Imaging Analysis of Pneumonic Plague Infection in Xizang, China: A Case Report and Literature Review. — Wang W, Li X, Wu J, Fu X, Li B. BMC Pulmonary Medicine. 2024.

6. Epidemiological and Diagnostic Aspects of the Outbreak of Pneumonic Plague in Madagascar. — Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. Lancet. 2000.

7. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.

8. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial Efficacy, 1939-2019. — Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2020.

9. Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.

10. Intervention to Stop Transmission of Imported Pneumonic Plague - Uganda, 2019. — Apangu T, Acayo S, Atiku LA, et al. MMWR. Morbidity and Mortality Weekly Report. 2020.